267 related articles for article (PubMed ID: 33508247)
1. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.
Muñoz-González JI; Álvarez-Twose I; Jara-Acevedo M; Zanotti R; Perkins C; Jawhar M; Sperr WR; Shoumariyeh K; Schwaab J; Greiner G; Henriques A; Caldas C; Fernández-Giménez C; Sánchez-Muñoz L; Mayado A; Pérez-Pons A; Schmitt-Graeff A; Duyster J; Tanasi I; Olivieri F; Mora-Casterá E; Luna I; Senent L; Bañas MH; Nuñez-García A; Jurado-Chacón M; Martín-Sánchez G; Colado E; Xicoy B; Gener-Ricós G; Gotlib J; Bonadonna P; Reiter A; Valent P; García-Montero AC; Orfao A
Lancet Haematol; 2021 Mar; 8(3):e194-e204. PubMed ID: 33508247
[TBL] [Abstract][Full Text] [Related]
2. MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis.
Jawhar M; Schwaab J; Álvarez-Twose I; Shoumariyeh K; Naumann N; Lübke J; Perkins C; Muñoz-González JI; Meggendorfer M; Kennedy V; Metzgeroth G; Fabarius A; Pfeifer D; Sotlar K; Horny HP; von Bubnoff N; Haferlach T; Cross NCP; Hofmann WK; Sperr WR; García-Montero AC; Valent P; Gotlib J; Orfao A; Reiter A
J Clin Oncol; 2019 Nov; 37(31):2846-2856. PubMed ID: 31509472
[TBL] [Abstract][Full Text] [Related]
3. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study.
Sperr WR; Kundi M; Alvarez-Twose I; van Anrooij B; Oude Elberink JNG; Gorska A; Niedoszytko M; Gleixner KV; Hadzijusufovic E; Zanotti R; Bonadonna P; Bonifacio M; Perkins C; Illerhaus A; Elena C; Merante S; Shoumariyeh K; von Bubnoff N; Parente R; Jawhar M; Belloni Fortina A; Caroppo F; Brockow K; Zink A; Fuchs D; Kilbertus AJ; Yavuz AS; Doubek M; Hägglund H; Panse J; Sabato V; Bretterklieber A; Niederwieser D; Breynaert C; Hartmann K; Triggiani M; Nedoszytko B; Reiter A; Orfao A; Hermine O; Gotlib J; Arock M; Kluin-Nelemans HC; Valent P
Lancet Haematol; 2019 Dec; 6(12):e638-e649. PubMed ID: 31676322
[TBL] [Abstract][Full Text] [Related]
4. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.
Jawhar M; Schwaab J; Hausmann D; Clemens J; Naumann N; Henzler T; Horny HP; Sotlar K; Schoenberg SO; Cross NC; Fabarius A; Hofmann WK; Valent P; Metzgeroth G; Reiter A
Leukemia; 2016 Dec; 30(12):2342-2350. PubMed ID: 27416984
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
Kluin-Nelemans HC; Jawhar M; Reiter A; van Anrooij B; Gotlib J; Hartmann K; Illerhaus A; Oude Elberink HNG; Gorska A; Niedoszytko M; Lange M; Scaffidi L; Zanotti R; Bonadonna P; Perkins C; Elena C; Malcovati L; Shoumariyeh K; von Bubnoff N; Müller S; Triggiani M; Parente R; Schwaab J; Kundi M; Fortina AB; Caroppo F; Brockow K; Zink A; Fuchs D; Angelova-Fischer I; Yavuz AS; Doubek M; Mattsson M; Hagglund H; Panse J; Simonowski A; Sabato V; Schug T; Jentzsch M; Breynaert C; Várkonyi J; Kennedy V; Hermine O; Rossignol J; Arock M; Valent P; Sperr WR
Theranostics; 2021; 11(1):292-303. PubMed ID: 33391475
[TBL] [Abstract][Full Text] [Related]
6. Response and progression on midostaurin in advanced systemic mastocytosis:
Jawhar M; Schwaab J; Naumann N; Horny HP; Sotlar K; Haferlach T; Metzgeroth G; Fabarius A; Valent P; Hofmann WK; Cross NCP; Meggendorfer M; Reiter A
Blood; 2017 Jul; 130(2):137-145. PubMed ID: 28424161
[TBL] [Abstract][Full Text] [Related]
7. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.
Jawhar M; Schwaab J; Schnittger S; Meggendorfer M; Pfirrmann M; Sotlar K; Horny HP; Metzgeroth G; Kluger S; Naumann N; Haferlach C; Haferlach T; Valent P; Hofmann WK; Fabarius A; Cross NC; Reiter A
Leukemia; 2016 Jan; 30(1):136-43. PubMed ID: 26464169
[TBL] [Abstract][Full Text] [Related]
8. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
9. Frequency and prognostic impact of
Muñoz-González JI; Álvarez-Twose I; Jara-Acevedo M; Henriques A; Viñas E; Prieto C; Sánchez-Muñoz L; Caldas C; Mayado A; Matito A; Dasilva-Freire N; Orfao A; García-Montero AC
Blood; 2019 Aug; 134(5):456-468. PubMed ID: 31151985
[TBL] [Abstract][Full Text] [Related]
10. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.
Jawhar M; Schwaab J; Meggendorfer M; Naumann N; Horny HP; Sotlar K; Haferlach T; Schmitt K; Fabarius A; Valent P; Hofmann WK; Cross NCP; Metzgeroth G; Reiter A
Haematologica; 2017 Jun; 102(6):1035-1043. PubMed ID: 28255023
[TBL] [Abstract][Full Text] [Related]
11. Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis.
Tefferi A; Shah S; Reichard KK; Hanson CA; Pardanani A
Am J Hematol; 2019 Jan; 94(1):E1-E2. PubMed ID: 30281840
[No Abstract] [Full Text] [Related]
12. Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis.
Lübke J; Naumann N; Metzgeroth G; Kreil S; Brand T; Horny HP; Sotlar K; Cross NCP; Fabarius A; Valent P; Hofmann WK; Reiter A; Schwaab J
Ann Hematol; 2023 Aug; 102(8):2077-2085. PubMed ID: 37012462
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels.
Kim HD; Cho H; Kim S; Lee K; Kang EH; Park JS; Park CS; Huh J; Ryu JS; Lee SW; Yoon DH; Kim SJ; Ko YH; Kim WS; Suh C
Cancer Res Treat; 2021 Jul; 53(3):847-856. PubMed ID: 33332932
[TBL] [Abstract][Full Text] [Related]
14. Impact of somatic and germline mutations on the outcome of systemic mastocytosis.
Muñoz-González JI; Jara-Acevedo M; Alvarez-Twose I; Merker JD; Teodosio C; Hou Y; Henriques A; Roskin KM; Sanchez-Muñoz L; Tsai AG; Caldas C; Matito A; Sánchez-Gallego JI; Mayado A; Dasilva-Freire N; Gotlib JR; Escribano L; Orfao A; García-Montero AC
Blood Adv; 2018 Nov; 2(21):2814-2828. PubMed ID: 30373888
[TBL] [Abstract][Full Text] [Related]
15. A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum β2-microglobulin levels.
Kim HD; Cho H; Jeong H; Bang K; Kim S; Lee K; Kang EH; Park JS; Park CS; Huh J; Ryu JS; Lee SW; Yoon DH; Oh SY; Suh C
Br J Haematol; 2021 Apr; 193(2):307-315. PubMed ID: 33216979
[TBL] [Abstract][Full Text] [Related]
16. Prognostic score including gene mutations in chronic myelomonocytic leukemia.
Itzykson R; Kosmider O; Renneville A; Gelsi-Boyer V; Meggendorfer M; Morabito M; Berthon C; Adès L; Fenaux P; Beyne-Rauzy O; Vey N; Braun T; Haferlach T; Dreyfus F; Cross NC; Preudhomme C; Bernard OA; Fontenay M; Vainchenker W; Schnittger S; Birnbaum D; Droin N; Solary E
J Clin Oncol; 2013 Jul; 31(19):2428-36. PubMed ID: 23690417
[TBL] [Abstract][Full Text] [Related]
17. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM.
Lübke J; Schmid A; Christen D; Oude Elberink HNG; Span LFR; Niedoszytko M; Gorska A; Lange M; Gleixner KV; Hadzijusufovic E; Stefan A; Angelova-Fischer I; Zanotti R; Bonifacio M; Bonadonna P; Shoumariyeh K; von Bubnoff N; Müller S; Perkins C; Elena C; Malcovati L; Hagglund H; Mattsson M; Parente R; Varkonyi J; Fortina AB; Caroppo F; Brockow K; Zink A; Breynaert C; Leven T; Yavuz AS; Doubek M; Sabato V; Schug T; Hartmann K; Triggiani M; Gotlib J; Hermine O; Arock M; Kluin-Nelemans HC; Panse J; Sperr WR; Valent P; Reiter A; Schwaab J
Blood Adv; 2024 Jun; 8(11):2890-2900. PubMed ID: 38593217
[TBL] [Abstract][Full Text] [Related]
18. Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival.
Pardanani A; Lasho T; Elala Y; Wassie E; Finke C; Reichard KK; Chen D; Hanson CA; Ketterling RP; Tefferi A
Am J Hematol; 2016 Sep; 91(9):888-93. PubMed ID: 27214377
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
20. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.
Escribano L; Alvarez-Twose I; Sánchez-Muñoz L; Garcia-Montero A; Núñez R; Almeida J; Jara-Acevedo M; Teodósio C; García-Cosío M; Bellas C; Orfao A
J Allergy Clin Immunol; 2009 Sep; 124(3):514-21. PubMed ID: 19541349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
